Nutriband Inc. (NTRB) 10-K Summary
Business Context and Reporting Period
Company: Nutriband Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 31, 2025
Business Overview: Nutriband is a clinical-stage biopharmaceutical company focused on developing transdermal pharmaceutical products. Its primary asset is the AVERSA™ abuse-deterrent technology, designed to prevent the misuse of opioid and stimulant patches. The company operates through two main subsidiaries: Pocono Pharmaceuticals (contract manufacturing and sales of goods) and 4P Therapeutics (R&D and contract research services).
Key Financial Metrics
| Metric | Year Ended Jan 31, 2025 | Year Ended Jan 31, 2024 |
|---|---|---|
| Revenue | $2,139,537 | $2,085,314 |
| Gross Profit | $743,317 | $862,105 |
| Gross Margin | 34.8% | 41.3% |
| Net Loss | $(10,482,617) | $(5,485,314) |
| Loss Per Share (Basic/Diluted) | $(0.99) | $(0.69) |
| Cash and Cash Equivalents | $4,311,719 | $492,942 |
| Working Capital | $3,811,420 | $22,770 |
| Total Debt (Notes Payable) | $186,349 | $207,009 |
Note: Revenue is derived primarily from Pocono Pharmaceuticals (contract manufacturing). 4P Therapeutics generated $0 revenue in 2025 compared to $165,034 in 2024 due to the winding down of a main contract.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss widened by approximately $5 million to $10.5 million, driven by a $3.6 million impairment charge on Goodwill and intangible assets, increased R&D expenses ($3.1M vs $2.0M), and higher SG&A expenses ($4.3M vs $3.8M).
- Liquidity Improvement: Cash balances increased significantly from $0.5 million to $4.3 million following an $8.4 million equity financing completed in April 2024.
- Impairment Charges: The company recorded a $3.6 million impairment charge, primarily reducing the value of Goodwill associated with the Active Intelligence reporting unit to zero.
- Revenue Stability: Total revenue remained relatively flat, though the mix shifted entirely to the sale of goods (Pocono), with no revenue from contract research services (4P Therapeutics).
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management believes the substantial doubt regarding the company's ability to continue as a going concern has been alleviated by the April 2024 financing and current cash position. The company estimates it requires approximately $13 million to complete the development of its lead product, AVERSA Fentanyl. As of January 31, 2025, approximately $3.0 million has been incurred, with an estimated $3.2 million remaining to complete the current work plan through NDA submission (following a February 2025 agreement amendment with Kindeva Drug Delivery).
Key Risks and Contingencies:
- Regulatory Risk: Success depends entirely on FDA approval of AVERSA Fentanyl via a 505(b)(2) NDA pathway. Delays or rejection would impair the ability to continue operations.
- Litigation: The company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP seeking over $500,000 in damages plus punitive damages regarding a terminated engagement letter. The company has filed counterclaims seeking $2 million.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties and reliance on third-party consultants.
- Capital Requirements: Continued operations and product development require substantial additional funding. Failure to raise capital could force a cessation of operations.
Investor Verification Checklist
- Cash Burn Rate: Verify the company's ability to fund the remaining $3.2 million for AVERSA Fentanyl development and ongoing operations with the current $4.3 million cash balance.
- Impairment Details: Review the valuation methodology used for the $3.6 million goodwill and intangible asset impairment to understand the impact on future asset valuations.
- Litigation Status: Monitor the discovery stage of the Gunnar/LB lawsuit and the potential impact of the $100,000 settlement offer or counterclaims.
- Internal Controls: Assess the timeline and effectiveness of management's plan to remediate material weaknesses in internal financial controls.
- Partnership Terms: Review the amended agreement with Kindeva Drug Delivery regarding the milestone payment structure ($3.0 million upon FDA approval) and its impact on future cash flow obligations.